{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:27Z","timestamp":1791005907487,"version":"4.1.0"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by granulomatous destruction of intrahepatic bile ducts. Current first-line treatments that delay liver damage but induce harmful side effects include ursodeoxycholic acid (UDCA), requiring lifelong administration among other complications, and obeticholic acid (OCA) associated with recurrent pruritus. In a recent breakthrough for PBC treatment, the Food and Drug Administration (FDA) granted accelerated approval for Iqirvo (elafibranor). A dual PPAR \u03b1\/\u03b4 agonist, it works by decreasing bile acid synthesis and increasing bile acid export, thereby reducing liver inflammation and limiting PBC progression. Based on the promising results from the ELATIVE phase 3 trial, which show significant reduction in alkaline phosphatase (ALP) levels and normalization of bilirubin levels, its approval can position Iqirvo as an ideal second-line treatment for PBC. Apart from mild gastrointestinal side effects and moderate drug interactions, Iqirvo is found to be safe and effective with a recommended daily dosage of 80 mg, marking a crucial advancement in the treatment landscape for PBC. This perspective explores the implications of Iqirvo\u2019s approval, highlights the need for continued innovation in PBC treatment, and discusses potential future directions for therapeutic strategies, including combination therapies and personalized approaches tailored to patient needs.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003395","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:00:11Z","timestamp":1748250011000},"page":"4017-4020","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0812-9477","authenticated-orcid":false,"given":"Shiza","family":"Abid","sequence":"first","affiliation":[{"name":"Ayub Medical College, Abbottabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sania","family":"Ghaffar","sequence":"additional","affiliation":[{"name":"Ayub Medical College, Abbottabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8611-5246","authenticated-orcid":false,"given":"Ahmad","family":"Qaisar","sequence":"additional","affiliation":[{"name":"FMH College of Medicine, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Bin Abid","sequence":"additional","affiliation":[{"name":"Frontier Medical and Dental College, Abbottabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6211-7522","authenticated-orcid":false,"given":"Kanza","family":"Farhan","sequence":"additional","affiliation":[{"name":"Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1595-2023","authenticated-orcid":false,"given":"Maimoona","family":"Akhtar","sequence":"additional","affiliation":[{"name":"Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-9368","authenticated-orcid":false,"given":"Mohammed","family":"Mahmmoud Fadelallah Eljack","sequence":"additional","affiliation":[{"name":"Community Department, University of Bakht Alruda, Ad Duwaym, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Goyal","sequence":"additional","affiliation":[{"name":"Seth GS Medical College and KEM Hospital, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"R3-20250922","first-page":"1","article-title":"Primary biliary cholangitis: advances in understanding and management","volume":"83","author":"Smith","year":"2022","journal-title":"Br J Hosp Med"},{"key":"R4-20250922","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/biomedicines10102464","article-title":"Obeticholic acid for primary biliary cholangitis","volume":"10","author":"Floreani","year":"2022","journal-title":"Biomedicines"},{"key":"R5-20250922","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"R7-20250922","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis |","journal-title":"N Engl J Med"},{"key":"R10-20250922","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:01:14Z","timestamp":1758524474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003395","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2025-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}